The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390 on ClinicalTrials.gov · last registry update 2026-08-24
An unusually large phase 3: 10,000 participants, more than double the 424 typical for the stage. Due to report February 2029, alongside 8 other tracked readouts that quarter. Primary outcome, as filed: Time to First Occurrence of Composite Endpoints. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 April 2024 — 2 years so far. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 10,000
- Started
- 2024-04-30
- Primary completion
- 2029-02 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to First Occurrence of Composite Endpoints
Conditions studied
Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.